Lindsay E. Lathrop

Lindsay E. Lathrop

Auto-generated profile, based on publicly available information

Lindsay E. Lathrop

Department of Microbiology, Immunology, & Molecular Genetics University of California, Los Angeles Los Angeles CA USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2026 in Advanced Functional Materials
Verified
Journal Article
Open access
RFRuth A. Foley
Ruth A. Foley
PAPaul George Ayoub
Paul George Ayoub
VSVrishti Sinha
Vrishti Sinha
CJColin Juett
Colin Juett
ASAlicia Sanoyca
Alicia Sanoyca
SJSteven J. Jonas
Steven J. Jonas
We report the engineering of lipid nanoparticles (LNPs) to transport CRISPR/Cas9 payloads, including linear double‐stranded DNA (ldsDNA) donor templates, designed for homology‐directed repair (HDR)‐mediated site‐specific insertion of the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene to correct cystic fibrosis (CF) in diseased airway epithelium. We screened various nanoparticle formulations, adjusting ratios of Cas9‐encoding mRNA, single guide RNAs (sgRNAs), and ldsDNA donor templates to optimize gene editing using human bronchial epithelial cells (16HBE14o‐) harboring a CF‐causing mutation (G542X). Populations of G542X cells edited via LNP delivery of CFTR donors achieved 3%–3.5% gene integration and yielded comparable CFTR protein expression compared to normal 16HBE14o‐ controls. These edited populations exhibit restoration of CFTR‐dependent Cl − current to ca. 80% of values measured in normal 16HBE14o‐ cell monolayers. This LNP platform adds capabilities for transporting large gene editing machinery to airway epithelial cells for genomic integration of entire genes, enabling therapeutic solutions that achieve correction of any CF‐causing mutation.

24 January 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
RFRuth A. Foley
Ruth A. Foley
PAPaul George Ayoub
Paul George Ayoub
VSVrishti Sinha
Vrishti Sinha
CJColin Juett
Colin Juett
ASAlicia Sanoyca
Alicia Sanoyca
SJSteven J. Jonas
Steven J. Jonas
We report the engineering of lipid nanoparticles (LNPs) to transport CRISPR/Cas9 payloads, including double-stranded DNA (dsDNA) donor templates, designed for homology directed repair (HDR)-mediated site-specific insertion of the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene to correct cystic fibrosis (CF) in diseased airway epithelium. We screened various nanoparticle formulations, adjusting ratios of Cas9-encoding mRNA, single guide RNAs (sgRNAs), and dsDNA donor templates to optimize gene editing using human bronchial epithelial cells (16HBE14o-) harboring a CF-causing mutation (G542X). Populations of G542X cells edited via LNP delivery of CFTR donors achieved 3 – 3.5% gene integration and yielded comparable CFTR protein expression compared to normal 16HBE14o- controls. These edited populations exhibit restoration of CFTR-dependent Cl- current to ca. 80% of values measured in normal 16HBE14o- cell monolayers. This LNP platform adds capabilities for transporting large gene editing machinery to airway epithelial cells for genomic integration of entire genes, enabling therapeutic solutions that achieve correction of any CF-causing mutation.

28 November 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
SYSang Pil Yoo
Sang Pil Yoo
XYXuegang Yuan
Xuegang Yuan
CEClaire Engstrom
Claire Engstrom
PCPatrick Chang
Patrick Chang
SLSuwen Li
Suwen Li
GCGay M. Crooks
Gay M. Crooks
Genetically modified, induced pluripotent stem cells (iPSCs) offer a promising allogeneic source for the generation of functionally enhanced, chimeric antigen receptor (CAR) T cells. However, the signaling of CARs during early T cell development and the removal of the endogenous T cell receptor required to prevent alloreactivity pose significant challenges to the production of mature conventional CAR T cells from iPSCs. Here, we show that TCR-null, CD8αβ CAR T cells can be efficiently generated from iPSCs by engineering stage-specific onset of CAR expression and signaling to both permit conventional T cell development and to induce efficient positive selection. CAR T cells produced using this approach displayed a uniform, naïve T cell phenotype and demonstrated superior antigen-specific cytotoxicity compared to iPSC-derived effector memory CAR T cells. Multimodal sequencing revealed CAR-mediated positive selection induced the persistent upregulation of key transcription factors involved in naïve T cell development. Achieving precise control of CAR expression and signaling in developmentally sensitive T precursors will be critical to realizing the full potential for “off-the-shelf”, iPSC-derived cellular therapies.

21 September 2025 in bioRxiv
Verified
Preprint
Open access
VSVrishti Sinha
Vrishti Sinha
PAPaul George Ayoub
Paul George Ayoub
CJColin J. Juett
Colin J. Juett
LLLindsay E. Lathrop
Lindsay E. Lathrop
RFRuth A. Foley
Ruth A. Foley
DKDonald Kohn
Donald Kohn
Cystic fibrosis (CF) is a devastating genetic disease caused by mutations in the Cystic Fibrosis Transmembrane Conductance Regulator ( CFTR ) gene. As morbidity and mortality from CF results from a lack of mucus clearance that leads to chronic bacterial infections and progressive loss of lung function, site-specific insertion of a CFTR cDNA into the endogenous CFTR locus in airway basal stem cells (ABSCs) could prove curative for all disease-causing mutations. This study describes the development of nonviral genome editing reagents, designed to be packaged into nonviral delivery systems. An sgRNA targeting the 5’ untranslated region of CFTR was characterized as directing high on-target cutting and displaying a safe off-target profile. Airway cell lines electroporated with chemically-modified (1-Aminohexane - AmC6), linear double-stranded DNA (ldsDNA) constructs were utilized as an Homology Directed Repair (HDR) donor, initially optimized with an mCitrine reporter. Expectedly, when the 780bp mCitrine cDNA was replaced with the 4.4kb CFTR cDNA, integration efficiency dropped significantly. However, 1-2% integration of codon optimized donors was sufficient to restore CFTR expression in the bulk edited population of human bronchial epithelial cell line, 16HBE14o- (16HBE), to levels reaching 50% of wildtype expression as measured by Western Blot. Electrophysiological validation of CFTR ion channel function measured via Ussing Chamber Assay revealed that these bulk edited populations exhibit greater than 40% restoration of the chloride ion currents of the measured wildtype controls. These results demonstrate that low levels of CFTR integration can be made therapeutically relevant by optimizing the designs of gene editing reagents. Importantly, this work utilizes nonviral editing reagents, an essential step towards in vivo gene therapy for CF.